CN113234676B - 一种促进鸭t细胞增殖的方法及其应用 - Google Patents
一种促进鸭t细胞增殖的方法及其应用 Download PDFInfo
- Publication number
- CN113234676B CN113234676B CN202110395246.3A CN202110395246A CN113234676B CN 113234676 B CN113234676 B CN 113234676B CN 202110395246 A CN202110395246 A CN 202110395246A CN 113234676 B CN113234676 B CN 113234676B
- Authority
- CN
- China
- Prior art keywords
- duck
- h5n1hpaiv
- pbmc
- cells
- memory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000272525 Anas platyrhynchos Species 0.000 title claims abstract description 65
- 230000006052 T cell proliferation Effects 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000001737 promoting effect Effects 0.000 title claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims abstract description 74
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 62
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 9
- 239000011886 peripheral blood Substances 0.000 claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 241000272522 Anas Species 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 48
- 230000035755 proliferation Effects 0.000 abstract description 13
- 241001473385 H5N1 subtype Species 0.000 abstract description 12
- 230000008859 change Effects 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 6
- 238000011529 RT qPCR Methods 0.000 abstract description 5
- 230000028993 immune response Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 description 15
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 12
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 11
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 238000005206 flow analysis Methods 0.000 description 8
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 101150118742 NP gene Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000005723 virus inoculator Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KQNZDYYTLMIZCT-KFKPYADVSA-N (2e,7s,10e,12r,13r,15s)-12,15-dihydroxy-7-methyl-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-9-one Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\C2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KFKPYADVSA-N 0.000 description 1
- BQRXMLXVGQMIBO-UHFFFAOYSA-N 1,1-bis(sulfanyl)ethanol Chemical compound CC(O)(S)S BQRXMLXVGQMIBO-UHFFFAOYSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004492 positive regulation of T cell proliferation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
Abstract
Description
试剂 | 用量 |
5×M-MLV-Mix | 4μL |
RNA | 6μL |
灭菌水 | 10μL |
总计 | 20μL |
试剂 | 用量 |
2*SYBR qPCR Master | 10μL |
FP | 0.5μL |
RP | 0.5μL |
ddH<sub>2</sub>O | 7μL |
cDNA | 10ng |
总计 | 20μL |
Claims (4)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110395246.3A CN113234676B (zh) | 2021-04-13 | 2021-04-13 | 一种促进鸭t细胞增殖的方法及其应用 |
NL2031234A NL2031234B1 (en) | 2021-04-13 | 2022-03-10 | Method for Promoting Duck T Cell Proliferation and Application Thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110395246.3A CN113234676B (zh) | 2021-04-13 | 2021-04-13 | 一种促进鸭t细胞增殖的方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113234676A CN113234676A (zh) | 2021-08-10 |
CN113234676B true CN113234676B (zh) | 2022-12-13 |
Family
ID=77128064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110395246.3A Active CN113234676B (zh) | 2021-04-13 | 2021-04-13 | 一种促进鸭t细胞增殖的方法及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113234676B (zh) |
NL (1) | NL2031234B1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116731965B (zh) * | 2023-05-30 | 2024-02-20 | 华南农业大学 | 一种免疫应答模型的建立方法、细胞应答测试方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202011652D0 (en) * | 2020-07-28 | 2020-09-09 | Univ Oxford Innovation Ltd | Polypeptide panels and uses thereof |
WO2022157288A1 (en) * | 2021-01-21 | 2022-07-28 | Cytovac A/S | Method for t-cell expansion and related medical applications |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2848614A1 (en) * | 2011-09-13 | 2013-03-21 | Sovicell Gmbh | An in-vitro process for the quick determination of the infection status of an infection with an influenza virus type |
CN103333224B (zh) * | 2013-05-10 | 2015-03-25 | 中国农业科学院哈尔滨兽医研究所 | 禽流感病毒ns1蛋白b细胞抗原表位多肽及其应用 |
JP6890831B2 (ja) * | 2015-07-08 | 2021-06-18 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Hiv予備免疫化および免疫療法 |
CN107365748A (zh) * | 2017-08-18 | 2017-11-21 | 路春光 | 外周血单个核细胞诱导的记忆性免疫细胞及应用 |
CN110747166B (zh) * | 2019-10-11 | 2021-07-09 | 厦门大学 | 一种外周血t细胞的体外扩增培养方法 |
-
2021
- 2021-04-13 CN CN202110395246.3A patent/CN113234676B/zh active Active
-
2022
- 2022-03-10 NL NL2031234A patent/NL2031234B1/en active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202011652D0 (en) * | 2020-07-28 | 2020-09-09 | Univ Oxford Innovation Ltd | Polypeptide panels and uses thereof |
WO2022157288A1 (en) * | 2021-01-21 | 2022-07-28 | Cytovac A/S | Method for t-cell expansion and related medical applications |
Also Published As
Publication number | Publication date |
---|---|
NL2031234A (en) | 2022-10-24 |
CN113234676A (zh) | 2021-08-10 |
NL2031234B1 (en) | 2022-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111330002B (zh) | 靶向冠状病毒的通用dc细胞疫苗及其制备方法和应用 | |
Sugden et al. | Clonal transformation of adult human leukocytes by Epstein-Barr virus | |
US9598671B2 (en) | Cyprinid herpesvirus II-sensitive brain tissue cell line of Carassius auratus gibelio and establishing method and use thereof | |
Hussey et al. | Innate immune responses of airway epithelial cells to infection with equine herpesvirus-1 | |
CN111450244B (zh) | 一种防治冠状病毒感染的细胞组合及其应用 | |
US20230065434A1 (en) | Preparation method of trophoblasts with limited generations, culture method of snk cells and method for treating tumor | |
CN113234676B (zh) | 一种促进鸭t细胞增殖的方法及其应用 | |
CN112410290A (zh) | 一种大口黑鲈心肌成纤维细胞系及应用 | |
Dai et al. | Comparative analysis of key immune protection factors in H9N2 avian influenza viruses infected and immunized specific pathogen–free chicken | |
CN116731965B (zh) | 一种免疫应答模型的建立方法、细胞应答测试方法 | |
CN114835778A (zh) | 一种h9n2亚型aiv mhc b2限制性表位肽及其应用 | |
CN115975924A (zh) | Ctl细胞的制备方法和应用 | |
EP3936611A1 (en) | Composition, culture medium and method for inducing and/or amplifying tscm in vitro | |
Nišavić et al. | Molecular detection of bovine herpesvirus 1 (BoHV-1) in cattle in Serbia | |
CN115094034A (zh) | 一种人nkt细胞系及其应用 | |
CN110951694B (zh) | 一种自体滋养细胞的制备方法和snk细胞的培养方法 | |
CN111154721A (zh) | Nk细胞扩增方法 | |
CN108210497B (zh) | 化合物mln4924在制备布尼亚病毒科白蛉病毒属病毒抑制剂的应用 | |
CN116948966A (zh) | 单倍型spf鸡细胞免疫应答模型的建立方法、细胞应答测试方法 | |
CN109735566B (zh) | 一种增强腺病毒载体生物制品感染靶细胞的方法 | |
CN105219710B (zh) | 一种高杀伤活性的免疫细胞群的培养方法 | |
CN115947869B (zh) | 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途 | |
Sandbulte et al. | T cells from a high proportion of apparently naive cattle can be activated by modified vaccinia virus Ankara (MVA) | |
CN108210880B (zh) | 化合物ps-341在制备布尼亚病毒科白蛉病毒属病毒抑制剂的应用 | |
CN116731953A (zh) | 弹状病毒阴性草地贪夜蛾昆虫细胞株及其筛选、鉴定和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240603 Address after: No. 483, Wushan, Tianhe District, Guangzhou City, Guangdong Province, 510610 Patentee after: SOUTH CHINA AGRICULTURAL University Country or region after: China Patentee after: GUANGZHOU SOUTH CHINA BIOLOGICAL MEDICINE Co.,Ltd. Address before: No. 483, Wushan, Tianhe District, Guangzhou, Guangdong 510630 Patentee before: SOUTH CHINA AGRICULTURAL University Country or region before: China Patentee before: INSTITUTE OF ANIMAL HEALTH, GUANGDONG ACADEMY OF AGRICULTURAL SCIENCES |